April 1, 2013
, the world leader in instruments and assay kits for measuring cell metabolism recently launched the XF Plasma Membrane Permeabilizer (PMP), a reagent that enables scientists to measure the biochemistry and mechanisms of mitochondrial dysfunction, without the need for mitochondrial isolation or detergent-based permeabilization methods.
XF PMP was developed in partnership with the Pioneer Valley Life Sciences Institute (PVLSI), a joint venture of Baystate Medical Center and the
University of Massachusetts Amherst
, with the dual missions of biomedical research and economic development. The technology was exclusively licensed to Seahorse Bioscience by
and Baystate Health, the parent organization of Baystate Medical Center.
XF PMP can be used with the Seahorse XF
Extracellular Flux Analyzer, an instrument for measuring cell metabolism, in real-time, in a microplate. The reagent was developed for XF technology in part by Dr.
, the John Adams Investigator at PVLSI; and Dr.
, Ph.D., an Assistant Professor of Biochemistry and Molecular Biology at
"In the development of this potent new tool in biomedical analysis, we see the tremendous potential of collaborations between clinical and academic researchers and ingenuitive companies like Seahorse," said
, M.D., Ph.D., chair of Pathology and chair of the Intellectual Property Committee at Baystate Health, who represented Baystate in working with Seahorse and
to establish the licensing agreement.
XF PMP creates pores in the cell plasma membrane, and delivers a degree of precision and ease-of-use that has not been available to scientists researching cell metabolism. A key element of XF PMP is the ability to assess mitochondrial function in adherent monolayers of permeabilized cells without damaging the mitochondrial membrane. By doing so, XF PMP enables metabolic substrates, compounds, and small proteins that otherwise would not cross the plasma membrane to reach the mitochondria.